2-year Treasury yield surges above 2.9% on hotter-than-expected inflation report

2-year Treasury yield surges above 2.9% on hotter-than-expected inflation report


Short-term U.S. Treasury yields popped Friday, after the release of hotter-than-expected inflation data raised concern over a possible recession.

The 2-year rate jumped more than 8 basis points to trade above 2.9%. The benchmark 10-year Treasury yield briefly rose before giving up those gains, last trading at about 3.04%. Short-term rates moved more due to their higher sensitivity to Federal Reserve rate hikes.

The U.S. consumer price index, a closely watched inflation gauge, rose by 8.6% in May on a year-over-year basis, its fastest increase since 1981, the Bureau of Labor Statistics reported Friday. Economists polled by Dow Jones expected a gain of 8.3%.

The so-called core CPI, which strips out volatile food and energy prices, rose 6%. That’s also above an estimate of 5.9%.

“So much for the idea that inflation has peaked,” Bankrate chief financial analyst Greg McBride said. “Any hopes that the Fed can ease up on the pace of rate hikes after the June and July meetings now seems to be a longshot. Inflation continues to rear its ugly head and hopes for improvement have been dashed again.”

Inflation has been surging all year, leading the Fed to raise rates in order to mitigate those pricing pressures.

The Fed started raising rates in March and implemented a 50-basis-point hike in May, its largest in 22 years, with the Federal Open Market Committee meeting minutes pointing to further aggressive increases ahead.

“I think what the market is going to focus on is what are the implications for the fed, not so much this month or July but September. That’s what people are all fired up about,” said Michael Schumacher of Wells Fargo.



Source

Merck shells out  billion for London-based lung therapy firm Verona
World

Merck shells out $10 billion for London-based lung therapy firm Verona

Bloomberg | Bloomberg | Getty Images Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s respiratory treatment portfolio in a bid to diversify its revenue source beyond blockbuster cancer drug. Merck has been leaning on its aging cancer immunotherapy Keytruda, the world’s top-selling prescription medicine, […]

Read More
Singapore state investor Temasek is rethinking defense as a strategic ESG bet
World

Singapore state investor Temasek is rethinking defense as a strategic ESG bet

Defense stocks are booming — and according to one of Asia’s biggest investors, allocating capital to the sector doesn’t mean having to abandon ESG initiatives. Speaking to CNBC’s Martin Soong on Wednesday, Rohit Sipahimalani, chief investment officer at Singapore’s state investment fund Temasek, said his team were looking at opportunities in the European defense sector. […]

Read More
Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push
World

Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push

Smart Ray-Ban Glasses, on June 16, 2024, in Caen, Normandy, France. Nurphoto | Getty Images Shares of Ray-Ban maker EssilorLuxottica almost 6% on Wednesday on reports that Meta has taken a minority stake in the company amid growing appetite for AI-powered wearable devices. Meta reportedly bought a stake worth around 3 billion euros ($3.51 billion) […]

Read More